Idiopathic anaphylaxis is a rare life-threatening disorder with symptoms similar to other forms of anaphylaxis. There is lack of a robust evidence base underpinning the treatment of anaphylaxis and even less so for idiopathic anaphylaxis. Much of the evidence therefore comes from relatively small case series and expert opinion. Idiopathic anaphylaxis is a diagnosis of exclusion, requiring a thorough history and careful diagnostic work-up investigating possible triggers and underlying predisposing factors. Key diagnostic tests include skin-prick testing, tests for specific-IgE, component-resolved diagnostics, and in some cases for allergen challenge tests. Other recognized causes of anaphylaxis, such as foods, medications, insect stings, latex, and exercise, should all be considered, as should differential diagnoses such as asthma. While the cause of idiopathic anaphylaxis remains unknown, prompt treatment with intramuscular epinephrine (adrenaline) administered into the anterolateral aspect of the thigh is associated with good prognosis. There may also be a role for H1-antihistamines and corticosteroids as second-line agents. Patients need to be carefully monitored for signs of deterioration and/or a possible protracted or biphasic reaction. Patients with frequent episodes of anaphylaxis (e.g., six or more episodes/year) should be considered for preventive therapy, which may include corticosteroids, H1-and H2-antihistamines, and, in some cases, mast cell stabilizers such as ketotifen. Alternative immune-suppressants (e.g., methotrexate) and anti-IgE may rarely also need to be considered. In many cases, the frequency of anaphylaxis declines such that regular use of corticosteroids can be discontinued after 9-12 months. Pediatric patients should be treated with similar regimens as adults, but with appropriate dose adjustments. Patients should carry their self-injectable epinephrine and other emergency medications at all times in order to deal with emergency situations.
Introduction
Anaphylaxis has been defined as a "…serious lifethreatening generalized or systemic hypersensitivity reaction," which is typically rapid in onset and associated with skin and mucosal changes; it may in some cases prove fatal [ [7] [8] [9] . Idiopathic anaphylaxis was first described by Bacal and colleagues in 1978 in a report of 11 patients whose episodes could not be explained [10••] . Although the actual incidence and prevalence of idiopathic anaphylaxis are difficult to estimate, it has been suggested that as of 1995 in the USA alone, there were, since it was first described, at least 50,000 patients with idiopathic anaphylaxis [6••, 11••, 12] . According to most reports, idiopathic anaphylaxis appears to be more common in females than in males, with several studies indicating that over 60% of cases are females [13, 14] . While idiopathic anaphylaxis was first reported amongst adults, subsequent reports show that it is a condition that may affect people of all ages, although it is more common in adults than in children [15] [16] [17] [18] .
Diagnosis
As the name indicates, the etiology of idiopathic anaphylaxis remains uncertain-it is therefore a diagnosis of exclusion In addition, other uncommon, so-called hidden food allergens should be considered as a differential diagnosis. An example of this is the so-called pancake anaphylactic syndrome or oral mite anaphylaxis, which is a new syndrome that presents with severe allergic symptoms and manifests after ingestion of foods made with mitecontaminated wheat flour, particularly pancakes [19, 20] .
Other [24] , and C4 (and in some cases C1inh) concentrations can be helpful if considering a diagnosis of hereditary angioedema [25] . All patients with a diagnosis of idiopathic anaphylaxis should be instructed in the management of an acute episode. This primarily involves early recognition of the condition and the prompt use of epinephrine. Patients/carers should be prescribed and instructed in the use of an epinephrine auto-injector and encouraged to carry it with them at all times along with an H1-antihistamine and corticosteroids
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. This advice is best communicated through a written and/or electronic self-management plan [27] .
Longer-term management of patients with idiopathic anaphylaxis is primarily determined by the frequency and severity of episodes and is initiated on an individual basis. There are no standard treatment regimens for this condition and limited robust research has been conducted. Treatments are based on case series, observations, and expert opinion . Caution should also be exercised to ensure that sedating H1-antihistamines are not used [31] . For long-term management, it is recommended to use a combined regimen of steroids and H1-antihistamines and there is evidence that up to 50% of patients go into remission after completing the recommended regimen [6••, 7, 11••]. Patients whose symptoms are not controlled with an H1-antihistamine may benefit from addition of H2-antihistamines [32] .
Emerging therapies Omalizumab
Omalizumab is a humanized monoclonal antibody that recognizes and binds to the Fc portion of the IgE molecule, thus blocking IgE binding to mast cells and basophils [33] [34] [35] [36] . It is a recognized treatment option for chronic, moderate, and severe persistent allergic asthma [37] and has also been shown to play important therapeutic role in other IgE-mediated conditions such as seasonal and perennial allergic rhinitis and chronic idiopathic urticaria [38] [39] [40] . Recently, in a series of case studies, omalizumab has been used to treat idiopathic anaphylaxis [33] [34] [35] [36] . Idiopathic anaphylactic patients administered 300-375 mg dose of omalizumab once every 2 to 4 weeks, after corticosteroid and antihistamine treatments did not reduce the frequency of attacks, were found to be without any anaphylactic episodes in about 6-12 months of using omalizumab [33] [34] [35] [36] . This is however an emerging therapy in the context of idiopathic anaphylaxis as it has only been demonstrated in a few cases. Omalizumab is a very expensive treatment regimen and there are current concerns that it can also in some cases cause anaphylaxis; therefore, patients receiving it require a period of observation after the injections [11••] .
Other agents
Ketotifen, an H1-antihstiamine and mast cell stabilizer, has been shown to be effective in reducing or terminating the dose of prednisone in corticosteroiddependent idiopathic anaphylaxis patients, although it has been shown to also cause severe sedation [6••, 11••, 41] and weight increase in children [42] . 
Pediatric considerations
Pediatric idiopathic anaphylactic patients should be classified and treated with similar regimens as adults but with dose adjustments for steroids, epinephrine, and antihistamines [2••]. Omalizumab is licensed for use in those 12 years and older [33] [34] [35] [36] .
Conclusions
Since it was first described 40 years ago, it has been possible to identify the trigger factor in a small proportion of those who previously would have been diagnosed as having idiopathic anaphylaxis. It remains a diagnosis of exclusion, which if appropriately treated is associated with a good prognosis. Selfinjectable epinephrine should be promptly administered intramuscularly and plans should then be made to transfer patients to an emergency department for monitoring. Repeated doses of epinephrine can be administered every 5-15 min, if necessary. Preventive approaches for those with frequent episodes include regular use of prednisone and non-sedating H1-antihistamines. Ketotifen, anti-leukotrienes, and omalizumab may all need to be considered to reduce the frequency of attacks and/or reduce the steroid load. Similar regimens used for treatment of idiopathic anaphylaxis in adults can also be used in the pediatric population although with appropriate adjustments of the doses of steroids, epinephrine, and antihistamines. It is hoped that further advances into the epidemiology and mechanisms of anaphylaxis will help to reduce the numbers of patients labelled as having idiopathic anaphylaxis.
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